<DOC>
	<DOCNO>NCT02580695</DOCNO>
	<brief_summary>Knee-osteoarthritis ( OA ) common disabling problem , represent global health issue since none current therapy truly disease modifying . The use mesenchymal stem cell ( MSCs ) OA-preclinical model associate reduction cartilage degradation , attenuation bone sclerosis effective anti-inflammatory response . Investigators design randomized phase I/II placebo control trial UC-MSCs knee OA . Outcomes evaluate 12 month , compare monodosis versus double intra-articular injection , re-randomized 6 month .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Umbilical Cord-derived Mesenchymal Stromal Cells Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Symptomatic Knee OA , Kellgren Lawrence grade I , II , III plain Rx film . Chondromalacia patella grade IIII knee MRI . With without meniscal tear . Stable knee normal clinical exam involve extremity Written inform consent patient . Bilateral symptomatic knee OA Local systemic infection . Active neoplasia immunosuppressive state Pregnancy Breastfeeding Body Mass Index â‰¥ 30 Presence Pacemaker Lower extremity metal implant Anticoagulant treatment aspirin . Recent use oral ( previous month ) intraarticular ( previous 3 month ) corticosteroid Concomitant inflammatory joint disease ( cristal , connective tissue disease ) Valgus ( &gt; 10o ) Varus ( &gt; 5o ) deformity involve extremity Condilar Tibial plateau Generalized Bone Marrow edema MRI Significant symptomatic hip spine disease Significant abnormality baseline lab test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>